INTRODUCTION
CC0 public domain photo by pixelcreatures Figure 1 -Access, Conservation, and Innovation are Interrelated Adapted from Hoffman and Outterson (2015) 2 To analyze political feasibility, we must consider how countries will act in the face of different proposed international agreements. Predicting how each country will act is a complex process because each country has its own considerations, history with AMR, and global standing. To facilitate our discussion, we describe four simplified types of countries that might be engaged in an AMR agreement: Initiator Countries, Pivotal Countries, Follower Countries and Neutral Countries.
Categories were created on the basis of surrogate measures for two important factors: (1) global influence, and (2) interest in addressing AMR.
STATE ACTOR TYPOLOGY
Global influence often depends on financial power. Thus, we used the World Bank's 2014 GDP rankings to categorize countries by global influence and designated the top 25% of countries by GDP as the most influential. 12 To categorize countries based on interest in addressing AMR, we looked to antibiotic consumption. We assume that countries that have seen recent large increases in antibiotic consumption have a greater stake in combating AMR than countries with low or stable consumption rates. yet, annual consumption rates, even standardized per capita, obscure underlying trends. For example, low rates of consumption and other nations. [15] [16] [17] [18] [19] In the USA, for example, the Food and Drug Administration successfully phased out non-treatment uses of medically important antibiotics in agriculture and plans to change OTC status, integrating industry perspectives in the process. [20] [21] [22] The agricultural industry in South Korea has also taken action. 23 
Pivotal Countries
Pivotal Countries are also highly influential with total GDPs falling within the top 25% globally. But these countries also have taken no action at all. These countries should be analyzed on a case-by-case basis to determine which type classification is most appropriate. Our complete methods for creating our typology are provided in the Appendix.
Initiator Countries
Initiator Countries are both highly influential-their GDPs fall within the top 25% globally-and saw substantial net decreases in human antibiotic consumption between 2000 and 2010. We theorize that these countries could be influential in initiating global action on AMR. Their success in decreasing antibiotic use makes these countries a potential source of expert knowledge on reducing antimicrobial use and AMR.
Further, these countries are most likely to have the resources and capacity to facilitate sustained action on AMR.
Mexico (MEX) is an example of an Initiator Country that has
taken steps towards reducing the threat of AMR with some CC0 public domain photo by skeeze 
Follower Countries

INFLUENTIAL STAKEHOLDERS
An important first step in analyzing the political feasibility of achieving global agreement on AMR is to identify key stakeholders who are likely to be affected by or play a role in AMR policies. At the international negotiation table, national representatives strive for agreements that promote common goals while remaining true to national priorities. 5 Domestically, key stakeholder groups influence national priorities by lobbying national governments to pursue policies favourable to their groups' interests. 4, 5 Where tensions arise between key stakeholder interests and international policies, so can barriers to international agreement. Figure 3 lists the key stakeholders we identified, and summarizes the interests and tensions these stakeholders bring to an AMR agreement.
antimicrobial use in animals, 35 as regulations focus primarily on products for export rather than the domestic market. 32 Countries in French West Africa (BEN, BFA, CIV, CMR, COG, GAB, GIN, MLI, SEN, TGO) face many barriers to acting on AMR without support. A lack of knowledge about local conditions is the biggest barrier. There is awareness that some AMR infections-such as MDR-TB-are a concern for the region, yet weak laboratory infrastructure means these countries lack drug resistance surveillance data. 36 Further, the lack of regulations and poor enforcement means that antibioticswhich are often of poor quality-can be dispensed from pharmacies and street vendors. 37 A great deal of capacity building would be required for these countries to take part in global AMR efforts. 42 An international AMR agreement may face challenges in reconciling these competing interests.
Neutral Countries
The pharmaceutical industry has expressed interest in participating in the AMR solution. In January 2016, 85 pharmaceutical companies and nine industry associations representing both generics and innovators signed a declaration committing to act on AMR and calling on governments to collaborate. 43 Thus, the pharmaceutical industry is well-positioned to engage in discussions on an international AMR agreement.
Agricultural Industry
The agricultural industry relies heavily on antimicrobials, and is a key player in the global discussion on AMR. In 1997,
an estimated 50% of all antimicrobials sold globally went to food animal production. 44 By 2030, livestock antibiotic use 
Pharmaceutical Industry
Stakeholders in the pharmaceutical industry include pharmaceutical innovators and generic drug manufacturers.
Innovators are key to antimicrobial R&D, and both innovators and generic manufacturers can influence access to and conservation of antimicrobials through pricing, education, and responsible marketing. 40 Adding an estimated $1.23 trillion to the global economy annually, the pharmaceutical industry has strong lobby power to impact political interests and health policies such as those addressing AMR.
4,41
The pharmaceutical industry's support for an international AMR agreement will likely depend on economic interests.
Antimicrobial R&D offers a poor prospect of financial return. Thus, governments could leverage this consumer demand to engage the industry in AMR discussions. 
Civil Society Organizations (CSOs)
BARRIERS TO INTERNATIONAL AGREEMENT
Barriers to creating an international agreement on AMR Figure 4 . Identified Barriers to a Global AMR Agreement
Agenda Setting Barriers
Creating an international AMR agreement requires consistent public and political engagement with the AMR issue. While political goals are often short-term due to election cycles, 34 AMR is a long-term battle that requires long-term funding.
Public engagement with health issues can influence the success of health policies, 4 
Barriers to Agenda Setting
which these practices exist in agriculture. 46 Economic and policy evaluations as well as intervention research would provide decision makers with better evidence to support policy decisions.
Agreement Formulation Barriers
A lack of data may also hinder AMR policy formulation. 
Agreement Implementation Barriers
To implement an international AMR agreement, actors and stakeholders will need to continue to cooperate at national and international levels. As with policy formulation, the challenge will be to reconcile stakeholder interests as well as international regulatory standards in a manner that At the most basic level, sanitation and infection control remain a problem in many places, and antibiotics are used as a stopgap to ensure patient safety.
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POLITICAL FEASIBILITY ANALYSIS
To effectively combat AMR, global action needs to address three key areas simultaneously: access, conservation, and innovation. Solving each of the access, conservation, and innovation problems will engage a different combination of stakeholders and interests, and each problem faces a different set of barriers in the policymaking cycle. Thus, the political feasibility of achieving coordinated global action on AMR depends on the likelihood that key actors can be engaged to overcome barriers to achieving global policies on access, conservation, and innovation.
Achieving Agreement on Access
Despite the growing problem of AMR, inadequate access to antibiotics still claims far more lives than antibiotic resistance. Key barriers to overcome: (1) lack of infrastructure, (2) financial constraints, and (3) human resource limitations.
Key actors and roles:
Initiator Countries, as well as a few select Pivotal Countries, must be engaged to provide resources and build capacity to overcome barriers in Follower and Pivotal Countries that struggle with inadequate access to antimicrobials.
Summary: Access Overcoming Resource and Capacity Limitations with
Leadership from Targeted Countries
Pivotal and Follower Countries both struggle with access problems, but often as a result of different contributing factors.
To improve access to antimicrobials, any proposed agreement will need to account for the complex background against which access issues arise in each country. For example, India has a high GDP and has a substantial generic pharmaceutical market, 84 yet it still struggles greatly with access. Thus, select Pivotal Countries such as India, despite having access problems, could contribute to the solution.
To address resource limitations, Initiator Countries could be engaged to provide financial support for access initiatives.
Some of these countries-such as the USA, the United Countries, surveillance is a broader conservation measure that requires global commitment and coordination.
Global Commitment to Overcoming Data Gaps
Lack of data on AMR in both humans and animals presents a Key barriers: (1) lack of data on AMR, and (2) global disparities in regulatory frameworks.
Key actors and roles:
While surveillance efforts must be undertaken on a global scale to be effective, engaging key Initiator and Pivotal Countries to strengthen regulatory frameworks on human and animal use of antimicrobials could greatly improve stewardship worldwide.
Summary: Conservation Targeted Commitment to Overcoming a Lack of Regulation
Global gaps in antimicrobial regulations, in both human and animal contexts, present a major barrier to implementing conservation efforts. 96 
P O L I T I C A L F E A S I B I L I T y A N A Ly S I S
Achieving Agreement on Innovation
The global AMR response must provide financial incentives 
Overcoming Capacity and Infrastructure Barriers with Initiator Countries
Initiator Countries with high interests and investments in pharmaceutical R&D should take the lead on antimicrobial innovation. 107 In fact, select Initiator Countries could tackle antimicrobial innovation alone. 76 High-income countries France-invest heavily in pharmaceutical R&D. 109 The USA has also identified investment in antimicrobial R&D as a key priority in its national strategy on AMR. 110 Initiator Countries are therefore best positioned to overcome any capacity or research infrastructure barriers associated with kick-starting the antimicrobial pipeline.
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Reconciling Key Stakeholder Interests in Initiator and
Pivotal Countries
Supporting pharmaceutical R&D sector interests will be a key concern for Initiator Countries with strong pharmaceutical markets in taking the lead on antimicrobial innovation.
Initiator Countries include most of the top eight developed pharmaceutical markets, where the pharmaceutical R&D sector accounts for nearly 75% of the market share and the provides the largest economic value-added of the pharmaceutical industry. 84, 111 Further, industry organizations can provide a powerful platform for members of the R&D sector to lobby national governments for health policies favouring R&D sector interests. 4, 112 In light of recent interest from the industry, 43 an innovation agreement that provides a mechanism for fair and sustainable compensation for antimicrobial R&D will likely see little resistance from the R&D sector.
Initiator Countries could receive opposition from the generic pharmaceutical industry if proposed strategies to incentivise innovation appear to limit the generic antimicrobial market in those countries. For example, generic manufacturers have opposed extending patent rights for innovators. 42 The global generic pharmaceutical industry is growing, 108, 109 and like pharmaceutical innovators, generic manufacturers can leverage powerful industry groups to lobby governments to protect their interests. 42 However, given the relative strength of the R&D sector in many Initiator Countries, and the expressed interests within these countries-including from generic Similarly, these countries will likely oppose an innovation agreement perceived to be unfavourable to the generic industry. Protecting generic pharmaceutical interests through, for example, engaging generic manufacturers in these countries to provide priority access to novel antimicrobials in low-income markets, 73 could facilitate support from Pivotal
Countries.
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Global Commitment to Overcoming Cost Distribution and Funding Barriers
While select Initiator Countries could solve the innovation problem alone, 76 an innovation agreement could leverage support from a broader range of countries to overcome policy formulation barriers of cost distribution and funding.
Key Initiator Countries are more likely to resist leading the innovation response if they perceive they will bear an unfair cost burden. 4 If new antimicrobials must be viewed as a "global public good", then all countries who benefit should contribute to creating that public good. 73 2. National governments, pharmaceutical companies, agriculture groups, civil society, and international organizations will be important stakeholders who must be engaged.
3. Many barriers to an international AMR agreement are likely to arise at different stages of the policy cycle, including agenda setting, agreement formulation, agreement legitimation, and agreement implementation.
4. For the purpose of assessing political feasibility of such an agreement, countries can be categorized into four types based on their global influence and potential interest in addressing AMR.
5. The political feasibility of an international agreement on AMR will depend on engaging a few key influential countries to develop policies that can eventually gain global traction.
Key Messages
a core group of countries could build the foundation that is necessary to develop a truly global and sustainable response.
Like a ripple effect, targeted measures could lead to much broader action. This phased-in approach is, in all likelihood, the most politically feasible way to achieve global agreement on AMR.
Global 
Country Typology Analysis
To analyse political feasibility, we must consider how countries will act in the face of different proposed international agreements. Predicting how each country will act is a complex process: each country has its own considerations, history with AMR, and global standing.
We describe four simplified types of countries that might increased usage greater than 50%, 30-50% increase, 10-29% increase, neutral (less than 10% increase or decrease), 10 to 29% decrease, and 50% or greater decrease. For countries that CDDEP reported as a group we chose to assign the group antibiotic consumption level to each country, and to use their individual GDP rankings. This is not precise but provides an estimate sufficient for our purposes in defining the typology.
This measure gives a long term overview of AMR change at the national level. Whether the country had high or low consumption rates in 2000, a large proportional increase in consumption signals a need to re-examine national priorities, while a decrease indicates successful stewardship efforts.
We plotted these GDP ranking and 10-year percent change in consumption against each other for 82 countries and developed the four types of countries illustrated in Figure 2 of our report.
Data labels use the three letter notations from the World Bank; a full listing of where the 82 countries under consideration fall is presented in Figure A1 . Our typology provides an organizing structure that assists in discussing the similarities of groups of countries. It was not possible to obtain newer data for a large number of countries and we recognize that some countries have made substantial progress more recently. We were also unable to capture animal use of antibiotics as this data is largely unavailable. We incorporate discussions of agricultural antibiotic use into our feasibility analysis to address this aspect of AMR.
Political Feasibility Analysis
Political feasibility has been described as an examination of actors and events in each stage of a policymaking process, and an anticipation of the likely resolution of the policy problem. 114 In defining political feasibility, Webber also outlined the goal of this type of analysis, which "… needs to assess the relative likelihood that a policy proposal or alternative, and a variety of modifications to that alternative, could be adopted
and implemented in such a way that the policy problem is solved. " Webber's staged approach is valuable because it breaks the policy process into stages that can be individually examined.
However, his approach necessitates having a clearly defined policy proposal as the starting point for a feasibility analysis.
We need to take a more generalist approach to our political feasibility analysis, as we do not have a draft global AMR agreement to use as a starting point. Meltsner has described a different strategy for political feasibility analysis, which is more amenable to our early-stage analysis. Under his system, the analyst identifies actors, their beliefs and motivations, resources, and the sites of their interaction. 115 Our analysis draws on both Meltsner's and Webber's methodologies. We adopt Webber's staged approach to analysis, using the well-known policy-cycle heuristic Our barriers analysis centres on the policy-cycle, which breaks the policymaking process into 6 stages. We have chosen to focus on the first four stages: agenda setting, policy formulation, policy legitimation, and policy implementation.
We identified important barriers in our literature review and key informant interviews, and categorized the in barriers by policy stage at which they are most problematic.
To determine the feasibility of policy proposals in Access, Innovation and Conservation, we considered the interlinkages between government priorities and capabilities, global AMR control needs, barriers to policy making, and stakeholder interests. On the basis of these factors we considered the likelihood that agreement on this issue could be achieved. Our analysis centres on rational choice theory: governments are expected to act on AMR in accordance with the best interests of their nation on matters of health and economics. 
